(February 13, 2007) Nanoparticles as Intracellular Targets to Produce RF-Induced Thermal Destruction of Cancer Cells
|What||ANH Breakfast Series|
February 13, 2007 12:00 PM
February 13, 2007 01:30 PM
February 13, 2007
from 12:00 pm to 01:30 pm
|Where||Fayez S. Sarofim Research Building|
|Add event to calendar||
The Alliance for NanoHealth is proud to announce its 2nd ANH Brunch Meeting on February 13, 2007. M.D. Anderson Cancer Center's Dr. Steven Curley will be featured as the event’s keynote speaker. You are cordially invited to attend this brunch session and encouraged to participate in the networking reception. Admission is free and open to the Texas Medical Center Community and Regional Academic Institutions.
Dr. Steven A. Curley is Professor of Surgery, the Charles B. Barker Chair in Surgery, Program Director of the Gastrointestinal Multidisciplinary Care Center, Chief of Gastrointestinal Tumor Surgery, and Director of the Surgical Oncology Fellowship Program at the University of Texas M.D. Anderson Cancer Center. Dr. Curley received his undergraduate education at the University of New Mexico, where he graduated Magna Cum Laude, Phi Beta Kappa with a Bachelor of Science degree in Biology and Biochemistry. He received his medical degree at the University of Texas Medical School at Houston, being elected to Alpha Omega Alpha as a junior, and then completed a general surgery residency at the University of New Mexico in Albuquerque. Following residency, he completed a fellowship in surgical oncology at the University of Texas M.D. Anderson Cancer Center, where upon completion of his fellowship, he joined the faculty. Dr. Curley is a Fellow of the American College of Surgeons and serves in the following groups: Colorectal Cancer Collaborative Clinical Trials, Colorectal Cancer Commission on Cancer Fellowship, Commission on Cancer Liver Disease Site Team and the American College of Surgeons Hepatobiliary Oncology Group. Dr. Curley=s major areas of interest are surgical treatments for patients with primary and metastatic liver cancers; the role of hepatitis B and C virus in hepatocellular cancer tumorigenesis; the development of novel treatment approaches for patients with primary and metastatic liver malignancies; neoadjuvant and adjuvant treatment approaches in patients with primary and metastatic hepatobiliary malignancies; and the development of targeted nanoparticle therapies in patients with advanced malignant diseases. Dr. Curley pioneered the clinical studies leading to FDA approval of radiofrequency ablation to treat unresectable primary and metastatic hepatobiliary malignancies. This has led to multidisciplinary trials to combine resection and radiofrequency ablation with adjuvant and neoadjuvant systemic and regional treatment to further improve patient outcome. He has been involved in the development of radiofrequency ablation equipment and treatment algorithms for patients with unresectable primary and metastatic hepatic malignancies. He has developed novel surgical techniques that have significantly reduced blood loss and operative time associated with major liver resections. He is Principal Investigator (PI) on a phase I/II trial studying ADI-PEG 20, a novel targeted drug therapy to treat patients with unresectable cancer. He recently initiated a new basic science research program to study biodistribution of carbon nanotubules and gold nanoparticles in normal and tumor tissue, and to use carbon nanotubules and gold nanoparticles as targeted therapy to treat malignant tumors with a novel external radiofrequency field generator. He is also PI of a program to screen high-risk hepatitis B and C virus patients for hepatocellular cancer in the Campania region of Italy. This study has been awarded a European Community Grant to extend the study to other high-risk areas in Europe. Dr. Curley has successfully translated from basic and preclinical studies human clinical trials for hepatic isolation infusion treatments for unresectable hepatocellular cancer and direct intratumoral injection of a collagen matrix mixed with chemotherapeutic agents. Dr. Curley has served a term as Chairman of the Graduate Medical Education Committee at the University of Texas M.D. Anderson Cancer Center and is currently the Course Director of the Research Ethics seminars and a member of the Clinical Council Subcommittee on Clinical Research Funding. Dr. Curley serves as an Associate Section Editor for the Annals of Surgical Oncology. He is also a member of the Editorial Boards for the following journals: Annals of Surgical Oncology, The Cancer Bulletin, International Journal of Surgical Sciences, Cancer Reports, Bulletin of the National Cancer Institute of Italy, European Journal of Surgical Science, International Journal of Surgical Investigation. Dr. Curley is a nationally-licensed soccer coach through the United States Soccer Federation and is still waiting to be asked to coach the U.S. Mens’ National team.
University Health Science Center at Houston
Fayez S. Sarofim Research Building
The Brown Foundation Institute for Molecular Medicine
1825 Pressler Street, Houston Texas
Beth Robertson Auditorium